c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of ICON7

Autor: Morgan, Robert, Ferreras, Cristina, Peset Martin, Isabel, Avizienyte, Egle, Renehan, Andrew, Edmondson, Richard, Murphy, Alexander, Nicum, Shibani, Van Brussel, Thomas, Clamp, Andrew, Lambrechts, Diether, Zhou, Cong, Jayson, Gordon

Publikováno v: Morgan, R, Ferreras, C, Peset Martin, I, Avizienyte, E, Renehan, A, Edmondson, R, Murphy, A, Nicum, S, Van Brussel, T, Clamp, A, Lambrechts, D, Zhou, C & Jayson, G 2022, ' c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of ICON7 ', BMC Medicine, vol. 20, 59 . https://doi.org/10.1186/s12916-022-02270-y

IntroductionBevacizumab improves survival outcomes in women diagnosed with epithelial ovarian cancer (EOC). Pre-clinical data showed that the c-MET/VEGFR-2 heterocomplex negates VEGF inhibition through activation of c-MET signalling, leading to a mor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3818::1af74d172759aea0fff4efa7339c16e9
https://research.manchester.ac.uk/en/publications/97ff8312-49c2-46b9-aeaf-72aa6317b132